Torsten Oliver Steinbrunn, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 17 | 2024 | 5189 | 1.300 |
Why?
|
Genes, ras | 4 | 2020 | 656 | 0.630 |
Why?
|
GTP Phosphohydrolases | 1 | 2020 | 523 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2012 | 2455 | 0.470 |
Why?
|
Electroporation | 1 | 2014 | 238 | 0.420 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2016 | 2877 | 0.410 |
Why?
|
Gene Knockdown Techniques | 6 | 2016 | 1601 | 0.340 |
Why?
|
Cell Survival | 7 | 2020 | 5745 | 0.320 |
Why?
|
MAP Kinase Signaling System | 3 | 2016 | 1489 | 0.320 |
Why?
|
Gene Transfer Techniques | 1 | 2014 | 1206 | 0.320 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2012 | 1239 | 0.290 |
Why?
|
Transfection | 1 | 2014 | 5738 | 0.260 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 3716 | 0.250 |
Why?
|
RNA, Small Interfering | 5 | 2016 | 3419 | 0.240 |
Why?
|
Mutation | 8 | 2023 | 30192 | 0.230 |
Why?
|
ADAM Proteins | 1 | 2024 | 243 | 0.210 |
Why?
|
Acetates | 1 | 2024 | 314 | 0.210 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1621 | 0.190 |
Why?
|
ral GTP-Binding Proteins | 1 | 2020 | 9 | 0.180 |
Why?
|
Signal Transduction | 6 | 2024 | 23597 | 0.170 |
Why?
|
ras Proteins | 2 | 2016 | 1054 | 0.160 |
Why?
|
Quinazolines | 1 | 2024 | 1366 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2024 | 837 | 0.140 |
Why?
|
Cell Line, Tumor | 6 | 2024 | 17060 | 0.130 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 729 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2021 | 615 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 2021 | 1609 | 0.120 |
Why?
|
Cell Proliferation | 2 | 2024 | 10426 | 0.110 |
Why?
|
HSC70 Heat-Shock Proteins | 1 | 2012 | 48 | 0.100 |
Why?
|
HSP72 Heat-Shock Proteins | 1 | 2012 | 40 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 478 | 0.100 |
Why?
|
Heat-Shock Proteins | 1 | 2016 | 790 | 0.100 |
Why?
|
Azo Compounds | 1 | 2012 | 115 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2024 | 3053 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1084 | 0.090 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2012 | 393 | 0.090 |
Why?
|
Genes, Reporter | 1 | 2014 | 1524 | 0.090 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2012 | 422 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 904 | 0.080 |
Why?
|
RNA Interference | 2 | 2016 | 2829 | 0.080 |
Why?
|
Protein Isoforms | 1 | 2014 | 1716 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3661 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8603 | 0.070 |
Why?
|
Gene Expression | 3 | 2016 | 7581 | 0.070 |
Why?
|
Drug Combinations | 1 | 2014 | 2075 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7847 | 0.070 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 1167 | 0.070 |
Why?
|
Cells, Cultured | 2 | 2014 | 18962 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13614 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2012 | 1331 | 0.070 |
Why?
|
Cell Death | 1 | 2012 | 1676 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2053 | 0.070 |
Why?
|
DNA Primers | 1 | 2010 | 2824 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5752 | 0.060 |
Why?
|
Humans | 19 | 2024 | 765926 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3594 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2014 | 5880 | 0.050 |
Why?
|
Thalidomide | 2 | 2019 | 886 | 0.050 |
Why?
|
Bone Marrow | 2 | 2023 | 2916 | 0.050 |
Why?
|
Germany | 1 | 2024 | 882 | 0.050 |
Why?
|
Pyrazoles | 1 | 2012 | 2031 | 0.050 |
Why?
|
Apoptosis | 2 | 2016 | 9505 | 0.040 |
Why?
|
Coordination Complexes | 1 | 2021 | 72 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10727 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5691 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2024 | 753 | 0.040 |
Why?
|
Base Sequence | 1 | 2010 | 12405 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9239 | 0.040 |
Why?
|
Peptides, Cyclic | 1 | 2021 | 390 | 0.040 |
Why?
|
Ikaros Transcription Factor | 1 | 2019 | 230 | 0.040 |
Why?
|
Ecosystem | 1 | 2021 | 489 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16039 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4859 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2023 | 1727 | 0.030 |
Why?
|
Gene Library | 1 | 2018 | 1066 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 598 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2021 | 3089 | 0.030 |
Why?
|
Isoenzymes | 1 | 2016 | 1688 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2021 | 2701 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13631 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2016 | 5333 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2016 | 3583 | 0.020 |
Why?
|
Homeostasis | 1 | 2021 | 3338 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 1894 | 0.020 |
Why?
|
Ligands | 1 | 2016 | 3272 | 0.020 |
Why?
|
Prognosis | 2 | 2023 | 29890 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2019 | 2897 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3586 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3940 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2057 | 0.020 |
Why?
|
Middle Aged | 4 | 2024 | 223016 | 0.020 |
Why?
|
Cell Membrane | 1 | 2016 | 3635 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22228 | 0.020 |
Why?
|
Aged | 3 | 2024 | 171163 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6766 | 0.020 |
Why?
|
Incidence | 1 | 2024 | 21513 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6838 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8279 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4780 | 0.020 |
Why?
|
Protein Binding | 1 | 2016 | 9296 | 0.010 |
Why?
|
Male | 4 | 2024 | 363815 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8492 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11030 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11196 | 0.010 |
Why?
|
Female | 3 | 2024 | 396141 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20133 | 0.010 |
Why?
|
Adult | 2 | 2024 | 223088 | 0.010 |
Why?
|
Young Adult | 1 | 2024 | 59857 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 59496 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 88811 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2024 | 81537 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11858 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81782 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2016 | 65194 | 0.010 |
Why?
|
Animals | 1 | 2021 | 168735 | 0.000 |
Why?
|